ALK and non-small cell lung carcinoma: A patient diagnosed with unresectable stage IIIA (cT1bN2M0) ALK-positive NSCLC underwent surgery to achieve a radical resection after neoadjuvant therapy with 3 months of lorlatinib and a pCR, which was confirmed by pathological analysis [43].